The Tumor and Host Response (TIHR) program is a newly developed, interdisciplinary research group that focuses on the interaction between immunity and cancer. Investigators of the TIHR program perform basic and translational research aimed at understanding the role of Immune/Inflammatory responses in the pathogenesis of cancer and the application of these discoveries to the treatment of cancer. The program is comprised of 20 members from six different departments with a total annual direct research support of $6,542,810 of which $1,786,734 is from the NCI. Over this last grant period, there were 352 publications of the Tumor Immunology and Host Response Program, of which 13,6% are intra-programmatic and 34.7% are inter-programmatic. Investigators are involved in many intra- and inter-programatic interactions and collaborate with researchers in other University of Michigan Comprehensive Cancer Center programs including Cancer Cell Biology, Breast Oncology, Prostate Oncology, and Head and Neck Oncology. The program has recently joined the Translational Research Cancer Consortium (TRC3), consisting of Immunology programs of major Comprehensive Cancer Centers in the region, The TIHR program has three main research themes: (1) to elucidate the mechanisms that regulate the interaction between cancer cells and the Innate and adaptive immune systems;(2) development of novel approaches to enhance immune responses against cancer cells;and (3) the translation of novel discoveries from the laboratory to the clinic for cancer treatment.
The program studies how the immune system interacts with tumor cells during cancer development. Our work will not only provide opportunity to induce better immune response for cancer prevention and therapy, but also elucidate critical host factors that facilitate cancer development for targeted cancer therapy.
|Verhaegen, Monique E; Mangelberger, Doris; Harms, Paul W et al. (2015) Merkel cell polyomavirus small T antigen is oncogenic in transgenic mice. J Invest Dermatol 135:1415-24|
|Chinn, Steven B; Darr, Owen A; Owen, John H et al. (2015) Cancer stem cells: mediators of tumorigenesis and metastasis in head and neck squamous cell carcinoma. Head Neck 37:317-26|
|Vainshtein, Jeffrey M; Spector, Matthew E; Stenmark, Matthew H et al. (2014) Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer. Oral Oncol 50:234-9|
|Castro, Maria G; Candolfi, Marianela; Wilson, Thomas J et al. (2014) Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther 14:1241-57|
|Vainshtein, Jeffrey M; Spector, Matthew E; McHugh, Jonathan B et al. (2014) Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. Oral Oncol 50:513-9|
|Grogan, Patrick T; Sarkaria, Jann N; Timmermann, Barbara N et al. (2014) Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Invest New Drugs 32:604-17|
|VanderVeen, Nathan; Paran, Christopher; Appelhans, Ashley et al. (2014) Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors. Mol Ther Methods Clin Dev 1:|
|Krook, Melanie A; Nicholls, Lauren A; Scannell, Christopher A et al. (2014) Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma. Mol Cancer Res 12:953-64|
|Ro, Seung-Hyun; Semple, Ian A; Park, Haewon et al. (2014) Sestrin2 promotes Unc-51-like kinase 1 mediated phosphorylation of p62/sequestosome-1. FEBS J 281:3816-27|
|Stenmark, Matthew H; McHugh, Jonathan B; Schipper, Matthew et al. (2014) Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys 88:580-8|
Showing the most recent 10 out of 862 publications